1 / 31

Update on the Replacement of the HCV RNA International Standard

Update on the Replacement of the HCV RNA International Standard. Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw 12-13 June 2007. Replacement of the 2 nd International Standard for HCV RNA (96/798).

ann
Download Presentation

Update on the Replacement of the HCV RNA International Standard

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw 12-13 June 2007

  2. Replacement of the 2nd International Standard for HCV RNA (96/798) • Proposal made at SoGAT 2005 to replace the HCV RNA International Standard as requested by WHO • Agreement that HCV 1a genotype would be sourced & would be anti-HCV negative and diluted in plasma rather than cryosupernatant

  3. Candidate Standards for Evaluation • 3 anti-HCV negative window period genotype 1a donations have been obtained • The genotype of each has been confirmed by LiPA & DNA sequencing • Absence of other viral markers confirmed in these stocks • Material has been freeze-dried in two batches • Batch 1 (NIBSC Code 06/100), 2085 vials, fill CV = 0.62% • Batch 2 (NIBSC code 06/102), 2100 vials, fill CV = 1.82%

  4. Panel for Collaborative study • Sample 1 – 2nd International Standard for HCV RNA (96/798) • Sample 2 - new freeze-dried preparation 06/100 • Sample 3 - new freeze-dried preparation 06/102 • Sample 4 – liquid/frozen bulk material (NIBSC code 06/118) that was used to prepare Samples 2 & 3

  5. Collaborative Study • Collaborative study commenced in November 2006 • Participants requested to test samples in four independent assays • 33 laboratories from 14 countries participated in the study • 40 data sets received; 25 from quantitative assays & 15 from qualitative assays • NIBSC collated & analysed data

  6. Types of Quantitative Assays Used by Participants

  7. Types of Qualitative Assays Used by Participants

  8. Estimated IU/ml (log10) from Quantitative Assays N - Number of laboratory estimates SD - Standard Deviation of log10 estimates across laboratories

  9. Estimated PCR Detectable Units/ml (log10) from Qualitative Assays N - Number of laboratory estimates SD - Standard Deviation of log10 estimates across laboratories

  10. Overall Mean Potencies (log10 IU/ml) Relative to Sample 1 N - Number of laboratory estimates SD - Standard Deviation of log10 estimates across laboratories

  11. Accelerated Degradation Studies Sample 2 • Relative potencies of accelerated degradation samples with respect to Sample 2 stored at -20ºC (log10 drop), qPCR analysis • Stability appears similar to 96/790 and 96/798; studies on-going • 96/798 from this study has not lost potency after >10 years storage at -20 ºC

  12. Proposal for 3rd International Standard for HCV RNA • Real-time & accelerated degradation data indicate that Sample 2 (06/100) is stable & suitable for long term use • Propose that 06/100 be established as the 3rd International Standard for HCV RNA with a unitage of 5.19 log10 IU/ml (4.89 log10 IU/vial) • Report will be submitted to ECBS by July

  13. Acknowledgements Nita Shah & David Padley NIBSC Professor Ewa Brojer, Institute of Hematology & Blood Transfusion, Warsaw Dr Richard Smith, National Genetics Institute, Los Angeles Dr Vivienne James, HPA, Colindale Dr Michael Chudy, WHO, Geneva Collaborative study participants

  14. HCV RNA Collaborative Study Participants • S Baylis, N Shah South Mimms, UK • T Cuypers M Koppelman Amsterdam, The Netherlands • C Defer Lille, France • L Fanning Cork, Eire • G Gesu Milan, Italy • A Goglio Bergamo, Italy • P Grant London, UK • P Iudicone Rome, Italy • L Jarvis, A Cleland Edinburgh, UK • C Jork Springe, Germany • S Kerby Bethesda, USA • A Klotz, M Gessner Vienna, Austria • R Madej Pleasanton, USA • B Miller Karlsruhe, Germany • S Mizusawa Tokyo, Japan • C Negru Timişoara, Romania • M Nübling Langen, Germany

  15. HCV RNA Collaborative Study Participants • JM Pawlotsky Créteil, France • M Pecorari Modena, Italy • G Pisani Rome, Italy • A Portela Moreira Madrid, Spain • S Sauleda Barcelona, Spain • H Schindl Vienna, Austria • G Schneider Des Plaines, USA • A da Silva Lisbon, Portugal • R Smith Los Angeles, USA • S Tassen Brentwood, UK • P Taylor London, UK • A van der Zanden Apeldoorn, The Netherlands • YC Yang Taipei, Taiwan • S Yerly Geneva, Switzerland • M Zaccanelli Treviglio, Italy

  16. Update on the Stability of the HAV RNA International Standard Sally Baylis, Nita Shah & Alan Heath, NIBSC SoGAT XX, Warsaw 12-13 June 2007

  17. Background – Hepatitis A Virus RNA IS • The 1st International Standard for HAV RNA (00/560) and a second batch (00/562) were prepared in Q1, 2001 • 00/560 was evaluated in an international collaborative study, with data returned from 16 laboratories • The mean log10 equivalents/ml were 5.29 (00/560) and 5.07 (00/562) • 1st International Standard (00/560) was established in 2003 with 50,000 IU/vial • ECBS noted that 00/562 may be a replacement for 00/560

  18. Stability Data 00/560 & 00/562 • Accelerated thermal degradation samples for 00/560 and 00/562, stored at +4ºC for ~6 years were tested in parallel with samples of 00/560 stored at -20 ºC • 00/560 – a drop on 0.1 log10 • 00/562 – a drop on 1.0 log10 • Conclude that 00/560 is highly stable

  19. Proposal to Replace the Parvovirus B19 DNA International Standard Sally Baylis, NIBSC SoGAT XX, Warsaw 12-13 June 2007

  20. Replacement of the Parvovirus B19 DNA IS 99/800 • The 1st International Standard for B19V DNA was established by the WHO ECBS in October 2000 • Estimated date of exhaustion of the IS will be 2008/9 at current rate of usage • Materials coded AA (99/800) & BB (99/802) showed no significant difference in potency in the collaborative study • ECBS noted that BB (made from the same stock as AA) could be reserved for potential future use as a replacement standard

  21. Candidate 2nd International Standard • Materials coded AA (99/800) & BB (99/802) showed no significant difference in potency in the original collaborative study • ECBS noted that BB (prepared from the same stock as AA) could be reserved for potential future use as a replacement standard • Current study designed to demonstrate the equivalence of the candidate replacement (BB) to AA • Real-time data on samples AA & BB • Accelerated degradation data for samples AA & BB

More Related